On October 29, Pfizer announced its 2024 Q3 financial report, with third-quarter revenue of $17.702 billion, a year-on-year increase of 32%.Excluding Comirnaty and Paxlovid, the total revenue from other products was $13.6 billion, a year-over-year increase of 14%. PfizerTotal revenue for the first three quarters was $45.864 billion, a year-on-year increase of 2%. Based on strong year-to-date performance, Pfizer has raised its full-year revenue guidance by $1.5 billion to an expected range of $61 billion to $64 billion.
In 2024 Q3, Pfizer's oncology business grew by 31% year-over-year, with its oncology revenue in the first half of the year reachingUnited StatesIn biopharmaceutical companiesRanked third. Among tumor products, PARP inhibitor Talzenna increased by 77% year-over-year, and BCMAxCD3 bispecific antibody Elrexfio surged 80% quarter-over-quarter, showing rapid growth.
Urogenital system tumors are a key focus area for Pfizer at present,Androgen receptor signaling inhibitor Xtandi (enzalutamide, +28%) andNectin-4 ADC Drug Padcev (Enfortumab Vedotin, Acquired fromSeagen) generated revenues of $506 million and $409 million respectively for Pfizer in itsRanked second and third in the list of oncology drug sales. The top-ranked isCDK4/6 Inhibitor Ibrance (Palbociclib), Its Q3 Sales Were1.087 billionDollar,A 12% year-on-year decrease.
In addition, the third-generation ALK inhibitor Lorbrena (lorlatinib) generated revenue of $206 million, representing a 31% year-over-year increase, while the BRAF/MEK inhibitor combination Braftovi/Mektovi achieved revenue of $173 million, marking a 32% year-over-year growth.。In December 2023, Pfizer acquired Seagen for $43 billion, gaining four ADC drugs, in addition to those mentioned above.Padcev (enfortumab vedotin) also includes targetedCD30-targeted Adcetris (Brentuximab Vedotin)HER2's Tukysa (Tucatinib), TargetedTivdak for Tissue Factor (TF). 2024Q3,The four ADC drugs from Seagen generated a total revenue of $8.54 billion for Pfizer.The sales of the anticoagulant drug Eliquis were 16.$170 million, an increase of 9% year-over-year. The product's market share in the United States and certain European markets may have increased due to its use in non-valvular atrial fibrillation indications, partially offsetting the impact of generic competition in certain international markets.
Rare Disease Drug: TafamidisThe revenue of Vyndaqel, Vyndamax, and Vynmac reached $1.447 billion, increasing by 63% year-over-year, mainly driven by strong demand for the drug in the U.S. and international developed markets. The sales of Nurtec ODT (Rimegepant), a headache medication, amounted to $337 million, marking a 45% year-over-year increase, with total prescriptions growing by 28%, maintaining its leading position in the oral CGRP class of drugs.
The Prevnar family (Prevnar 20&13) achieved sales of $1.803 billion, representing a year-over-year increase of 2%.Prevnar 20Prevnar 20 has already captured 83% and 97% of the market share in pediatrics and adults, respectively. Following the Advisory Committee on Immunization Practices (ACIP) recommendation last week to expand adult pneumococcal vaccination to all adults aged 50 and above, Prevnar 20 will further serve a broader population.RSV Vaccine Abrysvo Sales Reach $356 Million, with Market Share Outside Wholesalers Surpassing 50% in Retailers and Clinics; Retail Market Share Grows for Nine Consecutive Weeks, Now at 43%. Recently, the FDA Approved Abrysvo for Patients Aged 18-59 at Increased Risk of Lower Respiratory Tract Disease Caused by RSV, Further Expanding the Vaccine’s Eligible Population.
Paxlovid's revenue is27.03billion dollars, this result is better than Pfizer's expectations, compared to last year.Q3, an increase of nearly 2.5 billion US dollars year-on-year. The revenue of Comirnaty was 1.422 billion US dollars, increasing by 9% year-on-year.Pfizer's Q3 product pipeline has made good progress, whether in terms of regulatory approvals, Phase III clinical result readings, or the launch of key projects. As shown in the figure above, most projects are proceeding smoothly according to plan, but the Phase III clinical study of the gene therapy Fordadistrogene Movaparvovec for Duchenne muscular dystrophy did not meet its primary endpoint. Additionally,The Phase III clinical trial of mRNA Covid/Flu did not meet all primary endpoints.Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position.For reprinting, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
